ATRA

Atara Biotherapeutics, Inc. (ATRA) | Rumor.io

Atara Biotherapeutics

ATRA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,990

Bullish sentiment (50-day avg)0%

Price to earnings ratio3.82

Market capitalization84M

Earnings per share-1.54

Dividend yield (TTM)—

Revenue (annual)120.8M

Net income (annual)32.7M

Social

What share of all stock conversation is about ATRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

May 12

Atara Biotherapeutics, Inc. ($ATRA) announced a productive meeting with the FDA regarding a potential path forward to resubmitting the tab-cel Biologics License Application (BLA).
The company's financial results and operational progress for the first quarter of 2026 were announced, with a focus on cash burn and a registered 400 million shelf.
There is speculation about an upcoming dilution event, with some predicting a significant drop in price after a recent share offering, while others believe the stock may reach $17.96 before declining.

Generated by AI

Sentiment

Of the messages about ATRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0%	50.15% -26.74
Bearish	—	—	100%	49.85% +26.74

Bullish· May 8

Analysts are too conservative with their $20 price target, and a surge to this level is expected soon.
Institutional ownership is driving the stock, with 20% institutional ownership and a licensed orphan drug that has already been approved in Europe.
The stock has shown strong holding power, with buyers stepping in to support the price and a possible move to double digits soon.

Bearish· May 8

Atra Biotherapeutics, Inc. ($ATRA) may face significant dilution due to its need to raise $40 million to complete a year-long trial for a drug that may not receive approval.
The company's financial situation is precarious, with limited cash on hand and a history of being denied approval for its drug, which may lead to major dilution.
Atra Biotherapeutics' business model is characterized by dilution, with the company relying on share sales to fund research, making it a potential "dilution machine".

Generated by AI

Topics

Of the messages about ATRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	60%	5.05%
Earnings	—	—	0%	0.03%
Technical Analysis	—	—	40%	32.58%
Analysts	—	—	0%	31.12%
Controversies	—	—	0%	0.01%
Macro	—	—	0%	31.21%

Earnings· Nov 9

ATRA missed earnings per share (EPS) estimates, reporting a loss.
The company's reported loss exceeded analyst expectations by $0.04.
Earnings results for ATRA were below expectations.

Analysts· Dec 15

Citigroup downgraded Atara Biotherapeutics ($ATRA) to Sell from Buy, citing the stock as overvalued, with a new price target of $16.00.
Jefferies Group and William Blair reaffirmed their "Buy" ratings for Atara Biotherapeutics ($ATRA), despite some analysts expressing concerns about the stock's valuation.
Canaccord Genuity maintained a "Buy" rating for Atara Biotherapeutics ($ATRA), with a 35% success rate, while Citigroup's downgrade to Sell weighed on the stock's performance.

Announcements· Feb 26

Atara Biotherapeutics, Inc. (ATRA) saw a stock price increase amid a report of FDA inconsistency leading to the rejection of its cell therapy.
The company's NeutronX federal partnership positions it for growth, with 20-50M government contracts validating its capability.
ATRA's partnership with NeutronX opens new verticals, with government contracts expected to contribute to the company's growth.

Technical Analysis· May 7

The stock price of ATRA broke out above $8.60, with a strong volume increase, indicating potential momentum expansion.
The support zone of $7.00-$6.50 continues to act as a pivot for short-term bounce reactions, but moves in this area are largely rotational/scalp-driven unless the structure shifts.
ATRA has a strong weekly structure, with a potential catalyst-driven move, but price action remains range-bound and liquidity-dependent, requiring a sustained breakout above $8.60 to confirm momentum expansion.

Generated by AI

Community

Of the messages about ATRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	30%	8.3%
Newcomers	—	—	70%	91.7%

Regulars· Jan 12

The FDA has issued a Complete Response Letter (CRL) for Atara Biotherapeutics' Biologics License Application (BLA) for EBVALLO, a treatment for EBV+ PTLD, citing questions about the trial.
Atara Biotherapeutics and Pierre Fabre Pharmaceuticals plan to urgently interact with the FDA to find a path forward for the accelerated approval of EBVALLO, without which patients have limited treatment options.
The FDA's CRL has been criticized by Atara and Pierre Fabre, who argue that patients with EBV+ PTLD have extremely limited treatment options and a life expectancy of weeks to months.

Newcomers· Apr 4

New investors are focusing on understanding the news surrounding Atara Biotherapeutics, with several users sharing articles that explain the company's developments in a simple way.
The newcomers are discussing the potential of Atara Biotherapeutics' products, with some users sharing links to articles that highlight the company's innovative approaches to treating various diseases.
Many of the users are just discovering Atara Biotherapeutics and are sharing their initial reactions to learning about the company, including its ticker symbol and basic information about its products.

Generated by AI

News

Epstein-Barr Virus Market Set to Witness Growth with Emerging Immunotherapies and Vaccine Pipeline by 2036 – DelveInsight | Atara Biotherapeutics, Pierre Fabre Laboratories, Immunic Therapeutics

9d agoBarchart.com

Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health

19d agoBarchart.com

Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares

26d agoInvesting.com

Atara Biotherapeutics president and CEO sells $40,882 in shares

1mo agoInvesting.com

Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates

1mo agoInvesting.com

Also Discussed

Investors talking about ATRA also mention

#	Name	Attention
1	Biodesix, Inc.BDSX	0%0
2	Regenxbio Inc.RGNX	0%+0
3	AlloVir, Inc.ALVR	0%0
4	Agios Pharmaceuticals, Inc.AGIO	0%0
5	Autolus Therapeutics plc ADRAUTL	0%+0
6	Travere Therapeutics Inc.TVTX	0%0
7	Denali Therapeutics Inc.DNLI	0%new
8	IN8bio, Inc.INAB	0%0
9	TSVT - 2seventy bio, Inc.	——
10	Journey Medical Corp. Common StockDERM	0%0

Atara Biotherapeutics, Inc.

Healthcare
Biotechnology

Atara Biotherapeutics, Inc. is a biotechnology company focused on allogeneic T-cell immunotherapy. Atara Biotherapeutics develops off-the-shelf cell-based therapies designed to address serious diseases, including solid tumors, hematologic cancers, and autoimmune conditions. Its current portfolio centers on Epstein-Barr virus (EBV)-targeted T-cell programs and next-generation CAR T candidates, reflecting a platform built to harness donor-derived immune cells for precision treatment approaches. The company’s product development activities include therapies aimed at EBV-driven diseases and B-cell malignancies, positioning it within the broader cell therapy and immuno-oncology markets. Headquartered in Thousand Oaks, California, Atara Biotherapeutics serves the evolving demand for advanced immunotherapies that can be manufactured and deployed without traditional patient-specific cell engineering.

Website

Location

1280 Rancho Conejo Blvd

Thousand Oaks, CA, 91320

United States

Social

What share of all stock conversation is about ATRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

May 12

Atara Biotherapeutics, Inc. ($ATRA) announced a productive meeting with the FDA regarding a potential path forward to resubmitting the tab-cel Biologics License Application (BLA).
The company's financial results and operational progress for the first quarter of 2026 were announced, with a focus on cash burn and a registered 400 million shelf.
There is speculation about an upcoming dilution event, with some predicting a significant drop in price after a recent share offering, while others believe the stock may reach $17.96 before declining.

Generated by AI

Sentiment

Of the messages about ATRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0%	50.15% -26.74
Bearish	—	—	100%	49.85% +26.74

Bullish· May 8

Analysts are too conservative with their $20 price target, and a surge to this level is expected soon.
Institutional ownership is driving the stock, with 20% institutional ownership and a licensed orphan drug that has already been approved in Europe.
The stock has shown strong holding power, with buyers stepping in to support the price and a possible move to double digits soon.

Bearish· May 8

Atra Biotherapeutics, Inc. ($ATRA) may face significant dilution due to its need to raise $40 million to complete a year-long trial for a drug that may not receive approval.
The company's financial situation is precarious, with limited cash on hand and a history of being denied approval for its drug, which may lead to major dilution.
Atra Biotherapeutics' business model is characterized by dilution, with the company relying on share sales to fund research, making it a potential "dilution machine".

Generated by AI

Topics

Of the messages about ATRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	60%	5.05%
Earnings	—	—	0%	0.03%
Technical Analysis	—	—	40%	32.58%
Analysts	—	—	0%	31.12%
Controversies	—	—	0%	0.01%
Macro	—	—	0%	31.21%

Earnings· Nov 9

ATRA missed earnings per share (EPS) estimates, reporting a loss.
The company's reported loss exceeded analyst expectations by $0.04.
Earnings results for ATRA were below expectations.

Analysts· Dec 15

Citigroup downgraded Atara Biotherapeutics ($ATRA) to Sell from Buy, citing the stock as overvalued, with a new price target of $16.00.
Jefferies Group and William Blair reaffirmed their "Buy" ratings for Atara Biotherapeutics ($ATRA), despite some analysts expressing concerns about the stock's valuation.
Canaccord Genuity maintained a "Buy" rating for Atara Biotherapeutics ($ATRA), with a 35% success rate, while Citigroup's downgrade to Sell weighed on the stock's performance.

Announcements· Feb 26

Atara Biotherapeutics, Inc. (ATRA) saw a stock price increase amid a report of FDA inconsistency leading to the rejection of its cell therapy.
The company's NeutronX federal partnership positions it for growth, with 20-50M government contracts validating its capability.
ATRA's partnership with NeutronX opens new verticals, with government contracts expected to contribute to the company's growth.

Technical Analysis· May 7

The stock price of ATRA broke out above $8.60, with a strong volume increase, indicating potential momentum expansion.
The support zone of $7.00-$6.50 continues to act as a pivot for short-term bounce reactions, but moves in this area are largely rotational/scalp-driven unless the structure shifts.
ATRA has a strong weekly structure, with a potential catalyst-driven move, but price action remains range-bound and liquidity-dependent, requiring a sustained breakout above $8.60 to confirm momentum expansion.

Generated by AI

Community

Of the messages about ATRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	30%	8.3%
Newcomers	—	—	70%	91.7%

Regulars· Jan 12

The FDA has issued a Complete Response Letter (CRL) for Atara Biotherapeutics' Biologics License Application (BLA) for EBVALLO, a treatment for EBV+ PTLD, citing questions about the trial.
Atara Biotherapeutics and Pierre Fabre Pharmaceuticals plan to urgently interact with the FDA to find a path forward for the accelerated approval of EBVALLO, without which patients have limited treatment options.
The FDA's CRL has been criticized by Atara and Pierre Fabre, who argue that patients with EBV+ PTLD have extremely limited treatment options and a life expectancy of weeks to months.

Newcomers· Apr 4

New investors are focusing on understanding the news surrounding Atara Biotherapeutics, with several users sharing articles that explain the company's developments in a simple way.
The newcomers are discussing the potential of Atara Biotherapeutics' products, with some users sharing links to articles that highlight the company's innovative approaches to treating various diseases.
Many of the users are just discovering Atara Biotherapeutics and are sharing their initial reactions to learning about the company, including its ticker symbol and basic information about its products.

Generated by AI

Atara Biotherapeutics

Social

May 12

Bullish· May 8

Bearish· May 8

Earnings· Nov 9

Analysts· Dec 15

Announcements· Feb 26

Technical Analysis· May 7

Regulars· Jan 12

Newcomers· Apr 4

Epstein-Barr Virus Market Set to Witness Growth with Emerging Immunotherapies and Vaccine Pipeline by 2036 – DelveInsight | Atara Biotherapeutics, Pierre Fabre Laboratories, Immunic Therapeutics

Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health

Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares

Atara Biotherapeutics president and CEO sells $40,882 in shares

Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates

Also Discussed

Atara Biotherapeutics, Inc.

Company Information

Location

Epstein-Barr Virus Market Set to Witness Growth with Emerging Immunotherapies and Vaccine Pipeline by 2036 – DelveInsight | Atara Biotherapeutics, Pierre Fabre Laboratories, Immunic Therapeutics

Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health

Atara Biotherapeutics director Brian Cherry buys nearly $1m in shares

Atara Biotherapeutics president and CEO sells $40,882 in shares

Atara Biotherapeutics Inc earnings missed by $0.10, revenue fell short of estimates

Also Discussed

Social

May 12

Bullish· May 8

Bearish· May 8

Earnings· Nov 9

Analysts· Dec 15

Announcements· Feb 26

Technical Analysis· May 7

Regulars· Jan 12

Newcomers· Apr 4